China’s NHC Issues National Guidelines for Autism Intervention and Rehabilitation in Children – 2026 Edition Sets Standardized, Family‑Centered Care Framework Under the “Five‑Health” Action Plan

Beijing, China – 23 Sep 2026 – China’s National Health Commission (NHC) has released and published its official interpretation of the “Guidelines for Intervention and Rehabilitation of Children with Autism Spectrum Disorder (2026 Edition)” (《孤独症谱系障碍儿童干预康复指南(2026年版)》), the country’s standardized national playbook for screening‑linked intervention and rehabilitation services for children with autism spectrum disorder (ASD). The Guidelines were commissioned to advance implementation of the “Action Plan for Promoting the ‘Five Health’ of Children and Adolescents (2026–2030)” (儿童青少年”五健”促进行动计划) and to normalize ASD screening‑and‑intervention services nationwide.

Policy Snapshot

ItemDetail
Issuing BodyNational Health Commission of China (NHC), General Office
DocumentGuidelines for Intervention and Rehabilitation of Children with Autism Spectrum Disorder (2026 Edition) + official interpretation
Policy DriverImplementation of the “Five‑Health” Promotion Action Plan for Children and Adolescents (2026–2030)
ObjectiveStandardize ASD screening and intervention‑rehabilitation services for children
Clinical PremiseSpecific curative treatment for ASD etiology/pathogenesis remains limited; rehabilitation training is the primary intervention, with the optimal treatment window before age 6 — earlier intervention yields better outcomes
Structure6 parts: intervention goals, basic principles, intervention content, facilities & personnel, quality control, glossary + annexes
Effective TimelineNot disclosed

Guideline Framework – Six Core Components

  • Intervention Goals: Improve deficient behaviors; reduce non‑adaptive, non‑functional restricted interests and repetitive stereotyped behaviors; reduce and eliminate challenging behaviors; increase functional and adaptive behaviors; address coexisting problems and comorbidities; and enhance social adaptability and quality of life.
  • Basic Principles: Eight pillars — early intervention, individualized intervention, comprehensive intervention, scientific evidence‑based practice, long‑term high‑intensity programs, grassroots (primary‑care)‑led delivery, family participation, and social integration & support.
  • Intervention Content: Nine workstreams covering health education, intervention for deficient behaviors, intervention for non‑adaptive restricted interests/repetitive behaviors, challenging‑behavior intervention, coexisting problems and comorbidity management, family intervention, psychotherapy, digital‑intelligent (数智) intervention‑rehabilitation, and follow‑up care.
  • Facilities & Personnel: Standards defined across two dimensions — site conditions and staffing configuration for service delivery.
  • Quality Control: Multi‑tier oversight assigned to health administrative departments at all levels and to medical and health institutions delivering services.
  • Glossary & Annexes: Formal definitions for deficient behaviors, challenging behaviors, coexisting problems, comorbidities, individualized intervention‑rehabilitation plans, and family intervention; annexes detail age‑ and ability‑stratified intervention points, commonly used behavioral intervention strategies, challenging‑behavior management, and common coexisting‑problem interventions.

Clinical & Policy Context

  • Disease Profile: ASD is a neurodevelopmental disorder with onset in early childhood, characterized by impairments in social interaction and communication plus restricted interests and repetitive stereotyped behaviors. It typically follows a long‑term chronic course and may be accompanied by language delay, intellectual disability, self‑injurious and impulsive behaviors, and psychiatric or somatic comorbidities, causing varying degrees of impairment to social functioning and quality of life.
  • Early‑Window Emphasis: The interpretation reiterates that because specific etiology‑targeted therapies remain limited, rehabilitation training before age 6 is the decisive leverage point — a principle now embedded in national service standards.
  • Grassroots Delivery Model: The “primary‑care‑led” (基层为主) principle signals a policy shift of intervention capacity toward community and county‑level health institutions rather than concentrating care in tertiary hospitals.
  • Digital‑Intelligent Rehabilitation: The inclusion of 数智干预康复 (digital‑intelligent intervention) as one of nine content pillars formally recognizes technology‑assisted rehabilitation — a first‑class category in national ASD guidance.

Market Impact & Outlook

  • Service Standardization: The Guidelines establish the first unified national content, facility, staffing, and quality‑control specifications for pediatric ASD intervention‑rehabilitation, likely to shape provincial service catalogs, reimbursement discussions, and institutional accreditation.
  • Rehabilitation Sector Demand: Codifying “long‑term high‑intensity” and “family participation” principles points to sustained, multi‑year service demand for pediatric rehabilitation institutions, therapists, and training providers across the primary‑care network.
  • Digital Health Opportunity: Explicit endorsement of digital‑intelligent intervention opens a policy‑aligned lane for tele‑rehabilitation platforms, AI‑assisted assessment tools, and home‑based intervention software serving ASD families.
  • Diagnostics Linkage: Standardized screening‑intervention workflows under the “Five‑Health” plan should increase early identification rates, with downstream implications for developmental‑assessment services and related diagnostics.
  • Implementation Details Pending: Funding mechanisms, staffing quotas, and rollout timelines were not disclosed in the interpretation; provincial implementation plans are expected to follow.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding national implementation of China’s pediatric autism intervention guidelines, service capacity expansion, and digital‑health adoption. Actual outcomes may differ based on provincial execution, funding allocation, workforce availability, and subsequent policy issuances by the NHC and health authorities at all levels..-China Health Reform Pulse

Policy Source: https://www.nhc.gov.cn/fys/c100077/202609/4aa20e2af33d440880b485adcb8b33c3.shtml

NIFDC Batch Release Approves 86 Certifications for Vaccines, Diagnostics, and Blood Products – Rabies and Hepatitis B Lead the September 14–20, 2026 Weekly Cycle

Beijing, China – 20 Sep 2026 – The China National Institute for Food and Drug Control (NIFDC) published its weekly Batch Release Information Publicity Table covering September 14–20, 2026, granting release approval (予以签发) to 86 batches of vaccines, in‑vitro diagnostic reagents, and blood products submitted by 26 marketing authorization holders. All batches were certified by the NIFDC as the issuing lot‑release authority, with no refusals recorded in the publicity table for the period.

Batch Release Snapshot

ItemDetail
AuthorityChina National Institute for Food and Drug Control (NIFDC)
Publication TypeWeekly Batch Release Information Publicity Table
Coverage Period14–20 September 2026
Total Batches Certified86 (all “release approved”)
Composition72 vaccine batches, 12 diagnostic reagent batches, 2 blood product batches (Human Coagulation Factor VIII)
Marketing Authorization Holders26 domestic and foreign manufacturers
Imported Products2 batches (DiaSorin Italia S.p.A. UK Branch – HBsAg ELISA kits, import batch‑release certificates)
Expiry Date RangeMarch 2027 (nasal‑spray influenza vaccine) through June 2029 (Human Coagulation Factor VIII)
Lot SizesNot disclosed

Category Breakdown – 86 Certified Batches

Product CategoryBatchesMarketing Authorization Holder(s)
Recombinant Hepatitis B Vaccine (Hansenula polymorpha)18AIM Changxin Biological Pharmaceutical (sole supplier this cycle)
Lyophilized Human Rabies Vaccine (Vero Cell)15Fosun Yalifeng Dalian (6), Jiangsu Kangrun (3), Shanghai Rongsheng (3), Changchun Zhuoyi (3)
Measles‑Mumps‑Rubella (MMR) Live Attenuated Combined Vaccine9Beijing Institute of Biological Products
Influenza Virus Split Vaccine6Anhui Zhifei Longcoma (3), Zhejiang Tianyuan (2), Hualan Biological Vaccine (1)
Bivalent HPV Vaccine (Pichia pastoris)4Yuxi Walvax (Zerun) Biotechnology
Adsorbed Acellular DTP Combined Vaccine4Chengdu Institute of Biological Products
HBsAg Diagnostic Kit (ELISA)4DiaSorin Italia S.p.A. UK Branch (2, imported), Shanghai Kehua (2)
Lyophilized Human Rabies Vaccine (Human Diploid Cell)3Chengdu Kanghua (2), Chengda Biological Benxi (1)
Influenza Virus Subunit Vaccine3Zhongyi Anke (2), Jiangsu Zhonghui Yuantong (1)
HCV Antibody Diagnostic Kit (ELISA)3Beijing Jinhao (1), Shanghai Kehua (1), Intco XinChuang Xiamen (1)
EV71 Inactivated Vaccine (Human Diploid Cell)3Institute of Medical Biology, Chinese Academy of Medical Sciences
Meningococcal ACYW135 Polysaccharide Conjugate Vaccine (CRM197 carrier)2CanSino Biologics
Meningococcal A+C Polysaccharide Conjugate Vaccine2Chengdu Oulin Biotech
Nasal‑Spray Live Attenuated Influenza Vaccine2Changchun Baike Biological Technology
Treponema pallidum Antibody Diagnostic Kit (ELISA)2Shanghai Kehua (1), Intco XinChuang Xiamen (1)
HIV Antibody Diagnostic Kit (ELISA)2Shanghai Kehua
Human Coagulation Factor VIII2China Resources Boya Biopharmaceutical
Sabin Strain Inactivated Polio Vaccine (Vero Cell)1Sinovac Biotech
HIV Antigen/Antibody Diagnostic Kit (ELISA)1Zhuhai Livzon Diagnostics

Manufacturer & Product Highlights

  • Hepatitis B leadership: AIM Changxin Biological Pharmaceutical, an affiliate of the AIM (Vacuna) vaccine group, accounted for all 18 recombinant hepatitis B (Hansenula polymorpha) batches certified this week — the largest single‑product haul of the cycle.
  • Rabies segment depth: A combined 18 rabies vaccine batches were released across seven manufacturers, spanning both mainstream Vero‑cell platforms and premium human diploid cell products from Chengda Biological (Benxi) and Chengdu Kanghua, underscoring sustained competition in China’s post‑exposure prophylaxis market.
  • CanSino quadrivalent conjugate: CanSino Biologics (HKEX: 6185; SSE STAR: 688185) secured release of two lots of its ACYW135 meningococcal polysaccharide conjugate vaccine (CRM197 carrier) — certificates 批签中检20262481/2482, with dual sub‑lot structure (MAC/MYW components), expiring October 2028.
  • Sinopharm network output: Beijing Institute of Biological Products (9 MMR batches) and Chengdu Institute of Biological Products (4 acellular DTP batches), both under China National Biotec Group (CNBG) of Sinopharm, dominated pediatric Expanded Programme on Immunization (EPI) categories.
  • Sinovac polio: Sinovac Biotech (private) received release for one batch of its Sabin‑strain inactivated polio vaccine (Vero cell), supporting national polio eradication maintenance immunization.
  • Walvax HPV supply: All four bivalent HPV vaccine (Pichia pastoris) batches came from Yuxi Walvax (Zerun) Biotechnology, the manufacturing arm of Walvax Biotechnology (SZSE: 300142), extending the two‑dose domestic HPV franchise.
  • Blood products: China Resources Boya Biopharmaceutical (SZSE: 300294) certified two Human Coagulation Factor VIII lots with the longest shelf life in the table (expiry June 2029).
  • Diagnostics breadth: Shanghai Kehua Bio‑engineering led IVD releases with batches across HBsAg, HCV, HIV, and syphilis ELISA panels; Zhuhai Livzon Diagnostics (under Livzon Pharmaceutical Group) contributed an HIV antigen/antibody combo kit.

Market Impact & Outlook

  • Regulatory Gatekeeping: China mandates lot‑by‑lot batch release for all vaccines and blood products — every commercial lot must carry NIFDC certification before market entry, making the weekly publicity table a high‑fidelity, near‑real‑time indicator of domestic vaccine supply flow.
  • Flu Season Build‑Up: With 11 influenza vaccine batches across split, subunit, and nasal‑spray live‑attenuated formats from six manufacturers, the cycle signals active stockpiling ahead of the northern‑hemisphere autumn–winter immunization campaign.
  • Pediatric Program Continuity: The concentration of MMR and DTP releases from CNBG institutes points to steady replenishment of state‑procured EPI vaccine inventories for the autumn enrollment vaccination window.
  • Import Channel Functioning: The two DiaSorin HBsAg kit certifications (批签中(进)检 series) confirm the import batch‑release pathway remains routine for foreign IVD suppliers serving Chinese blood‑screening and hospital markets.
  • Supply Quantification Limits: The publicity discloses certificates, batch numbers, and expiry dates but not lot volumes; dose‑level supply estimates cannot be derived from this release.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding vaccine supply continuity, procurement timing, and seasonal immunization demand in China. Batch‑release certification confirms regulatory clearance of specific lots only; actual market availability, tender awards, and distribution volumes may differ based on procurement dynamics and manufacturer planning..-China Health Reform Pulse

Policy Source: https://www.nidc.org.cn/directory/web/nifdc/xxgk/ggtzh/jwgk/shwzhppfgg/202609221454042215080.html

China Launches Electronic Customs Clearance Pilot for Imported Drugs at Beijing Port – NMPA and GACC Grant Digital Documents Equal Legal Force

Beijing, China – 16 Sep 2026 – China’s National Medical Products Administration (NMPA) and the General Administration of Customs of China (GACC) jointly announced the launch of an electronic customs clearance pilot program for imported drugs (including medicinal crude materials) at Beijing Port, effective from the date of announcement. Under the pilot, electronic clearance documents carry the same legal force as their paper counterparts, marking a milestone in the digitization of China’s pharmaceutical import supervision.

Policy Snapshot

ItemDetail
Issuing AgenciesNMPA and General Administration of Customs of China (GACC)
Policy TypePilot program for electronic customs clearance documentation
ScopeImported drugs, including medicinal crude materials (药材)
Pilot LocationBeijing Port
Effective Date16 Sep 2026 (from date of announcement)
Legal StatusElectronic clearance documents have equal legal force with paper documents
Transition ArrangementPaper documents remain valid during the pilot; enterprises may continue using them per existing regulations
Expansion TimelineNot disclosed

Policy Details & Legal Framework

  • Objective: Further advance the digitalization of government services and improve the efficiency and convenience of customs clearance for imported drugs and medicinal materials.
  • Legal Parity: For the first time at the pilot port, electronic clearance documents are granted the same legal validity as paper documents — a critical enabler for fully digital cross-border pharmaceutical trade workflows.
  • Dual‑Track Transition: During the pilot period, the existing paper documentation remains valid, allowing importers to adopt the electronic channel at their own pace without operational disruption.
  • Joint Governance: The announcement was co‑issued by the drug regulator (NMPA) and the customs authority (GACC), reflecting cross‑agency coordination between product regulation and border control in pharmaceutical imports.

Industry Context

  • Legacy Paper Burden: Pharmaceutical imports into China have traditionally required paper‑based clearance certificates at ports of entry, adding administrative steps and courier logistics to time‑sensitive shipments.
  • Digital Trade Facilitation: The pilot aligns with China’s broader push to digitize government services and cross‑border trade documentation, including electronic customs declaration and paperless clearance reforms.
  • Inclusive Scope: By explicitly covering medicinal crude materials (药材) alongside finished drugs, the pilot addresses a segment historically subject to specialized port inspection requirements.
  • Strategic Entry Point: Beijing Port — served by Capital International Airport and Daxing International Airport cargo facilities — is a key gateway for imported pharmaceuticals, biologics, and temperature‑sensitive products.

Market Impact & Outlook

  • For Importers: Multinational pharmaceutical companies, distributors, and trading firms importing finished drugs, APIs, and herbal materials through Beijing can expect streamlined clearance procedures and reduced paperwork, lowering administrative costs.
  • Supply Chain Resilience: Electronic documentation reduces dependence on physical transport of clearance certificates, benefiting cold‑chain and urgent humanitarian shipments.
  • Regulatory Signal: The pilot may serve as a template for broader rollout to other major ports should it prove successful; no expansion timeline or additional ports have been disclosed.
  • Compliance Note: Enterprises operating dual‑track documentation should ensure internal systems can reconcile electronic and paper records during the transition period.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding regulatory implementation timelines, pilot expansion, and operational expectations for electronic customs clearance of imported drugs in China. Actual outcomes may differ due to factors including administrative execution at port level, enterprise adoption rates, and subsequent policy adjustments by the NMPA and GACC..-China Health Reform Pulse

Policy Source: https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20260921091608111.html